Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map[®] in Europe
OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for the distribution of the GA-map® Dysbiosis Test in Europe.GA and the diagnostic partner are now in the launch phase for selected European markets and expect this to fuel revenues from 2023. There is increasing demand for gut microbiome assessments in the private healthcare service, medical clinics, and academic research globally. The GA-map® product offering will target labs performing